

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/261291067>

In vitro–in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against *Mycobacteria tuberculosis*

ARTICLE *in* TUBERCULOSIS (EDINBURGH, SCOTLAND) · MAY 2014

Impact Factor: 2.71 · DOI: 10.1016/j.tube.2014.03.007

CITATION

1

READS

33

5 AUTHORS, INCLUDING:



Susan E Brown

Colorado State University

71 PUBLICATIONS 1,786 CITATIONS

SEE PROFILE



Kunal Kumar

Stony Brook University

11 PUBLICATIONS 153 CITATIONS

SEE PROFILE



Iwao Ojima

Stony Brook University/State University of ...

494 PUBLICATIONS 12,949 CITATIONS

SEE PROFILE




Richard A Slayden

Colorado State University

68 PUBLICATIONS 2,773 CITATIONS

SEE PROFILE



DRUG DISCOVERY AND RESISTANCE

In vitro–*in vivo* activity relationship of substituted benzimidazole cell division inhibitors with activity against *Mycobacterium tuberculosis*Susan E. Knudson^a, Kunal Kumar^c, Divya Awasthi^b, Iwao Ojima^{b,c}, Richard A. Slayden^{a,*}^a *Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA*^b *Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA*^c *Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY 11794-3400, USA*

ARTICLE INFO

Article history:

Received 2 December 2013

Received in revised form

4 March 2014

Accepted 23 March 2014

Keywords:

Mycobacterium tuberculosis

Benzimidazole

In vivo efficacy

FtsZ inhibitor

Murine model tuberculosis

In vitro activity

SUMMARY

Structure based drug design was used to develop a compound library of novel 2,5,6- and 2,5,7-trisubstituted benzimidazoles. Three structural analogs, SB-P1G10, SB-P8B2 and SB-P3G2 were selected from this library for advanced study. *In vitro* studies revealed that SB-P8B2 and SB-P3G2 had sigmoidal kill-curves while in contrast SB-P1G10 showed a narrow zonal susceptibility. The *in vitro* studies also demonstrated that exposure to SB-P8B2 or SB-P3G2 was bactericidal, while SB-P1G10 treatment never resulted in complete killing. The dose curves for the three compounds against clinical isolates were comparable to their respective dose curves in the laboratory strain of *Mycobacterium tuberculosis*. SB-P8B2 and SB-P3G2 exhibited antibacterial activity against non-replicating bacilli under low oxygen conditions. SB-P3G2 and SB-P1G10 were assessed in acute short-term animal models of tuberculosis, which showed that SB-P3G2 demonstrated activity against *M. tuberculosis*. Together, these studies reveal an *in vitro*–*in vivo* relationship of the 2,5,6-trisubstituted benzimidazoles that serves as a criterion for advancing this class of cell division inhibitors into more resource intensive *in vivo* efficacy models such as the long-term murine model of tuberculosis and Pre-IND PK/PD studies. Specifically, these studies are the first demonstration of efficacy and an *in vitro*–*in vivo* activity relationship for 2,5,6-trisubstituted benzimidazoles. The *in vivo* activity presented in this manuscript substantiates this class of cell division inhibitors as having potency and efficacy against *M. tuberculosis*.

© 2014 Elsevier Ltd. All rights reserved.

1. Background

It is estimated that a third of the world's population is infected with *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB), and between 5 and 10% of those infected individuals will develop active disease over their lifetime. As a result, TB is the second leading cause of death from an infectious disease and the leading cause of death from a bacterial infection worldwide [1]. In addition, to the global burden, the increasing rates of multi-drug resistant strains (MDR-TB) that require extensive treatment regimens with second line drugs impact disease management [2,3]. Therefore, there is a need to develop new therapeutics with unique modes of action that can be co-administered with existing antitubercular drugs.

Cell division has been proposed as an attractive target for the development of new chemotherapeutics against *M. tuberculosis* [4]. Of all the components involved in bacterial cell division, two proteins FtsZ and FtsI are the best characterized and are therefore receiving the most attention with regards to drug discovery [5–7]. Although, FtsZ and tubulin share structural and functional homology, we have demonstrated that specificity for the mycobacterial FtsZ can be obtained through medicinal chemistry efforts [8,9]. Importantly, this affords the opportunity to use known pharmacophores such as, pyridopyrazine, pteridine and benzimidazole, as starting points for SAR optimization [6,7]. Specifically, selected 2,5,6- and 2,5,7-trisubstituted benzimidazoles developed through rational drug design, have demonstrated potency with low or negligible cytotoxicity [9].

In drug development, it is often difficult to apply appropriate criteria to prioritize and advance drugs through the drug discovery pipeline. Most often, the advancement of lead compounds into animal models of infection to assess efficacy is based primarily on

* Corresponding author.

E-mail address: Richard.Slayden@ColoState.edu (R.A. Slayden).

minimal inhibitory concentration and cytotoxicity [10]. Often, lack of efficacy is attributed to poor bioavailability or drug exposure. However, there is historical evidence that the bactericidal activity of some antimicrobials might not increase with additional concentrations of drug [11]. Rather, these compounds display a multi-modal kill-curve characterized by a narrow range of concentrations that result in effective bactericidal activity. A more recent study described that drug treatment can instigate a tolerant phenotype by eliciting stress responses, which is consistent with this phenomenon, and the common observation of tolerance to treatment [12,13].

Previously, eleven 2,5,6- and 2,5,7-trisubstituted benzimidazoles were identified with varying potency against *M. tuberculosis* [9]. In this study, we evaluated in more detail the three 2,5,6-trisubstituted benzimidazoles, SB-P1G10, SB-P3G2 and SB-P8B2, for activity against clinical strains and non-replicating bacilli, and determined the kill-curve characteristics of the compounds. SB-P1G10 and SB-P3G2 were assessed for efficacy in murine models of tuberculosis. These studies revealed an *in vitro*–*in vivo* activity relationship of the anti-TB benzimidazoles exhibiting efficacy in a murine model of tuberculosis. Importantly, the identification of an *in vitro*–*in vivo* activity relationship can serve as a criterion for advancing next generation cell division inhibitors into more resource intensive efficacy models such as the long-term murine model of tuberculosis and Pre-IND PK/PD studies.

2. Methods

2.1. *M. tuberculosis* strains and drug treatment conditions

M. tuberculosis H37Rv and Erdman (TMCC 107) strains are drug sensitive laboratory reference strains used in the MIC studies [9,14], and the tuberculosis animal models of infection [15–17]. The clinical isolates W210, NHN20, NHN382 and TN587 have varying drug susceptibility profiles [4,18]. For the *in vitro* studies all strains were grown in Difco™ 7H9 Middlebrook liquid media (BD Biosciences, 271310) supplemented with 10% Middlebrook OADC Enrichment (VWR, 9000-614), 0.05% Tween (G-Biosciences, 786-519), and 0.2% Glycerol at 37 °C. *M. tuberculosis* was grown on Difco™ Middlebrook 7H11 agar (BD Biosciences, 283810) supplemented with 1% Asparagine and antibiotics for colony forming unit (CFU) assays from animal studies. Antibiotics used were carbenicillin 50 mg/L (Sigma, C1389) and cycloheximide 10 mg/L (Sigma, C7698). Antibiotics and asparagine were not included in agar plates used for CFUs from *M. tuberculosis in vitro* assays. Three 2,5,6-trisubstituted benzimidazoles, SB-P1G10, SB-P3G2 and SB-P8B2, were synthesized as described previously [9].

2.2. *In vitro* growth and bactericidal assays

MIC values were determined for the benzimidazoles using a modified 96-well microplate Alamar Blue assay (MABA) [9,19]. For time dose studies, bacterial growth in the presence of compound was monitored by the O.D. 600 nm. Each compound was assessed at a number of concentrations relative to the MIC in triplicate every 24 h over 5 days by O.D. 600 nm and confirmed by plating at days 0, 1, 3, 5 of drug exposure. For the dose–response curves, the bacterial viability in the presence of different concentrations of each compound was determined using the MABA assay. Bacteria were treated for 7 days before assessing viability. The values were plotted against time using GraphPad (www.graphpad.com).

2.3. *In vitro* low oxygen studies

The low oxygen studies were performed similar to those described previously [20]. Briefly, *M. tuberculosis* H37Rv were

diluted to an O.D. 600 nm of 0.003 in 7H9 media containing Methylene Blue (1.5 µg/mL) and were grown in 16 × 125 mm Hungate tubes with rubber septa. The tubes, with 11 mL of the diluted cultures were incubated at 37 °C under agitation (150 rpm). Methylene blue was monitored for color change indicating that oxygen was depleted from the system. One week after the reduction of methylene blue; approximately 28 days from the start, drug treatment was initiated with the test and control drugs. Prior to treatment, an aliquot was removed and plated for a CFU count to serve as a control. Isoniazid and metronidazole were used in the studies as comparative controls at two concentrations 4 µg/mL and 45 µg/mL. Recovery of aliquots for plating and the addition of drugs were conducted through septa using syringes to maintain the low-oxygen conditions. 96 h Post-treatment, 1 mL of the culture was removed from the oxygen depleted cultures, the aliquot was serially diluted and the dilutions were plated. CFUs were calculated for the different treatments and concentrations. Percentage growth reduction from the controls was calculated and reported.

2.4. *In vitro* drug combination studies

A checkerboard 96 well plate method was used to examine possible antagonism or synergy between the 2,5,6-trisubstituted benzimidazoles and rifampicin (RIF). Drugs were distributed in 2-fold dilutions in a checkerboard pattern in a 96 well plate starting with 2× MIC for each drug tested in combination. *M. tuberculosis* H37Rv cells were added to the plate to a final well volume of 200 µL. No growth and positive growth controls were included in the assay. After 6 days incubation at 37 °C, Alamar Blue was added. The fractional inhibitory concentrations (FICs) were calculated to determine synergy in the drug combinations as described [21]. FIC is defined as the MIC of a drug in combination divided by the MIC of that drug alone. The fractional inhibitory index (FICI) is the sum of the FIC (ΣFIC) for the drugs tested in the combination. Drugs are considered synergistic when the ΣFIC is less than 0.5, indifferent when the ΣFIC is between 0.5 and 4, and antagonistic when the ΣFIC is greater than 4.

2.5. Rapid murine models of tuberculosis used for efficacy screening

Compound efficacy was assessed in two murine models of infection based on the typical [short term] rapid model described previously and the standard mouse model [16]. All aerosol infections were performed using a Middlebrook aerosol generation devise (Glas-Col, Terre Haute, IN). In the first infection short term model, immune incompetent C57BL/6-lfngtm1ts gamma interferon gene disruption (GKO) mice were infected with *M. tuberculosis* H37Rv. Animals were dosed q.d. IP beginning day 12 post-infection with 150 mg/kg of compound in 38% Ethanol and 10% Solutol for 9 consecutive days. In the second animal model, immune competent C57BL/6 mice were infected with *M. tuberculosis* Erdman (TMCC 107). Animals were dosed b.i.d. IP with 100 mg/kg compound in 25% Ethanol and 25% Solutol beginning day 5 post-infection for 10 consecutive days. Isoniazid was used as a comparative positive control and was delivered q.d. at 25 mg/kg. Different delivery vehicles were used for each model to accommodate the difference in drug dosing volumes and number of dosings per animal per study. In both studies, animals were sacrificed and necropsied, bacterial burden in lungs and spleens were quantified on 7H11 agar containing carbenicillin (Sigma, C1389) and cycloheximide (Sigma, C7698) and upon incubation for three weeks bacterial colony forming units were enumerated. Outliers were identified by the Grubbs' Test and one-way *t*-test at a 95% confidence interval was used to compare treatment groups and controls, to calculate *p*-

values, and to produce bar graphs and scatter plots GraphPad Prism (www.graphpad.com).

3. Results

3.1. In vitro potency of benzimidazoles against *Mtb* H37Rv and Erdman strains

We previously reported the discovery of a novel class of benzimidazoles that demonstrated antibacterial activity against *M. tuberculosis* and representative clinical isolates with various drug susceptibility profiles [9]. For these studies, the MIC of the candidates, SB-P1G10, SB-P3G2 and SB-P8B2 (Figure 1) was confirmed against *M. tuberculosis* H37Rv and Erdman strains. This revealed that SB-P8B2 and SB-P3G2 had similar MIC ranges of 0.39–0.78 µg/mL and 0.78–1.5 µg/mL, respectively, and SB-P1G10 exhibited a slightly higher MIC range of 3–6.25 µg/mL. Therefore, the experimental MIC ranges of these compounds are comparable based on typical CLSI drug guidelines, and as previously reported [9], the benzimidazoles SB-P8B2 (1b-G1 [9]), SB-P3G2 (1a-G7 [9]) and SB-P1G10 (1a-G3 [9]) did not exhibit appreciable cytotoxicity against the standard Vero cell line resulting in therapeutic indices of greater than 512 to 32, respectively.

3.2. Combination of SB-P8B2 with rifampicin

Since compounds whose mode of action is inhibition of cell division have not been evaluated for potential antagonistic interactions with currently used first line TB drugs, the compound with the lowest MIC, SB-P8B2, was used in combination with rifampicin as a representative of the mode of action of this novel class of compounds. This was assessed in a checkerboard *in vitro* growth inhibition assay (Table 1). The potency of both rifampicin and SB-P8B2 was enhanced by the presence of the other, resulting in a ΣFIC of 0.63. Specifically, SB-P8B2 was 8 times more potent in the presence of rifampicin and SB-P8B2 doubled the activity of rifampicin, thus indicating that there was enhanced killing using a combination of SB-P8B2 and the first line anti-TB drug rifampicin.

3.3. In vitro growth inhibition and bactericidal action

Bacterial growth was monitored in the presence of SB-P3G2, SB-P8B2 or SB-P1G10 at concentrations relative to the MIC for 5 days to evaluate the inhibition in bacterial growth rate (Figure 2). The growth curves for the three benzimidazoles examined were all dose-dependent and not time-dependent. The growth inhibition

Table 1
Enhancement of drug activity (MIC) with combination treatment.

Drug	Alone	In combination	ΣFIC ^a
SB-P8B2 [†]	1 × MIC	0.1 × MIC	0.63
Rifampicin	1 × MIC	0.5 × MIC	

^aMIC was determined by MABA [9].

* ΣFIC is the sum of the FICs (MIC of a drug in combination/MIC of that drug alone) for all the drugs tested in the combination. Drugs are considered synergistic when the ΣFIC is less than 0.5 and antagonistic when the ΣFIC is greater than 4.

[†] SB-P8B2, was used in combination with rifampicin as a representative of this novel class of FtsZ cell division inhibitors.

curves for SB-P3G2 and SB-P8B2 were similar, showing that inhibition of bacterial growth correlated with increased drug concentrations (Figure 2A). Bacterial growth was inhibited at concentrations greater than 0.62 µg/mL and 0.31 µg/mL for SB-P3G2 and SB-P8B2, respectively. The bacterial growth in the presence of 0.78 µg/mL, 1.56 µg/mL, 3.13 µg/mL, 6.26 µg/mL and 12.5 µg/mL of SB-P1G10 was characterized by different rates (Figure 2B). At 3.13 µg/mL SB-P1G10 by O.D. 600 nm data appeared to be cidal but the plating and enumeration of CFUs indicated that the bacteria were still viable (Figure 2C). Additional dose response studies confirmed this observation (data not shown).

To understand the kill characteristics of SB-P3G2, SB-P8B2 and SB-P1G10, the compounds were tested for bactericidal activity at different concentrations (Figure 3). Bacteria treated with either SB-P3G2 or SB-P8B2 demonstrated the typical sigmoidal bactericidal curve exhibited by the frontline therapeutic INH, indicating that as the compound concentration increased the percent viable bacteria decreased to a minimal population at which no additional killing was observed (Figure 3A and B). In contrast, SB-P1G10 did not display a typical sigmoidal bactericidal curve. Rather, bactericidal activity was achieved in a very narrow concentration range of SB-P1G10, from 0.5 to 4 fold of MIC (Figure 3C). The resulting pronounced zonal susceptibility curve is characteristic of the Eagle–Musselman phenomenon where optimal effective killing is centered on the MIC, and at greater concentrations the bacteria remain viable in a bacteriostatic state [11]. To assess whether the observed kill characteristics were applicable to clinical isolates, the dose–response curves for SB-P3G2, SB-P8B2 and SB-P1G10 were generated against the clinical isolates W210, NHN20, NHN382 and TN587. Notably, not only are the MIC values of each of the compounds against the *M. tuberculosis* clinical strains comparable to the MIC for the H37Rv laboratory strain, but the dose curves generated for each compound against the clinical isolates examined in this study and H37Rv were remarkably similar (data not shown).

3.4. Activity of select benzimidazoles against non-replicating *M. tuberculosis* grown in low oxygen conditions

As part of our ongoing efforts on the development of FtsZ inhibitors as anti-TB agents, we extended the previous study by assessing the activity of benzimidazoles against non-replicating *M. tuberculosis* H37Rv in low oxygen conditions. Based on the confirmed MIC against *M. tuberculosis* H37Rv and the kill-curve characteristics, SB-P3G2 and SB-P8B2 were tested for potency against non-replicating bacteria in low oxygen conditions (Table 2). Metronidazole and INH were included as controls to confirm that the cultures were under low oxygen conditions during treatment. Both SB-P3G2 and SB-P8B2 showed greater activity against non-replicating bacilli than isoniazid, which is known to not have potent activity against non-replicating bacteria. SB-P8B2 and SB-P3G2 at 4 µg/mL reduced the survival of *M. tuberculosis* H37Rv by 59% and 72%, respectively (Table 2). Notably, SB-P3G2 at 4 µg/mL




Figure 1. Drug structures. Chemical structures for the three 2,5,6-trisubstituted benzimidazoles discussed in the text.




Figure 2. Growth inhibition curves. Bacterial growth was assessed in the presence of different concentrations of (A) SB-P3G2 and SB-P8B2 and (B) SB-P1G10 by optical density. (C) The growth inhibition of SB-P1G10 in panel B was validated by plating and enumeration of bacterial outgrowth (log₁₀ CFU/mL). The different drug concentrations were tested in triplicate at each time point and the mean and standard deviation of the values for the different doses were plotted.

reduced the growth comparable to metronidazole at 4 µg/mL. SB-P8B2 at 45 µg/mL reduced the growth of bacteria by almost 1 log₁₀ CFU. In conclusion, the substituted benzimidazoles SB-P3G2 and SB-P8B2 have activity against non-replicating *M. tuberculosis* resulting from low oxygen conditions.

3.5. *In vitro*–*in vivo* activity relationship

SB-P3G2 and SB-P1G10 were used in two different animal models of acute tuberculosis infection to investigate the *in vitro*–*in vivo* activity relationship between benzimidazoles with the two disparate kill-curve characteristics. These animal models are used in our drug discovery program because they afford the ability to evaluate if a drug candidate can reduce the bacterial load during an acute infection and inhibit dissemination from the site of infection to secondary sites. In the first acute infection animal study which uses immune incompetent GKO mice, SB-P3G2 reduced the bacterial load of *M. tuberculosis* H37Rv by 0.71 ± 0.17 log₁₀ CFU in the lungs and 0.41 ± 0.36 log₁₀ CFU in spleen (Figure 4A) [16]. Isoniazid reduced the bacterial load 1.8 log₁₀ CFU in the lung and below the level of detection in the spleen. In the second dissemination model of infection using immune competent C57BL/6 mice, SB-P3G2 reduced the bacterial load of *M. tuberculosis* Erdman in the spleen by log₁₀ 1.6 ± 0.49 (Figure 4B). Isoniazid reduced the bacterial load in the lung and spleen below detectable levels. In the different animal models tested, SB-P3G2 always showed some level of detectable efficacy. Together, these animal studies show that SB-P3G2 has efficacy against an acute infection and can prevent dissemination to secondary sites. In contrast, treatment with SB-P1G10 never reduced the bacterial load in the lungs or spleen in

the animal model of infection conducted (data not shown). This data indicates that two of the benzimidazoles with similar physicochemical and *in vitro* potency against *M. tuberculosis*, but different *in vitro* inhibition kill-curve characteristics demonstrate distinctly different efficacy outcomes.

4. Discussion

The goal to reduce the global burden of tuberculosis has been hampered by difficult to treat chronic infections and the emergence of MDR strains of *M. tuberculosis* that are resistant to the frontline drugs or drug combinations needed to achieve durable cure. While drug discovery programs continue to make progress, there often remains a disconnect between a drug candidate's *in vitro* potency and its observed efficacy in animal models of infection, which limits the number of lead candidates advancing to Pre-IND and clinical evaluation. We believe that this disconnect, in part, can be attributed to differences in a compound's kill characteristics. The susceptibility of bacteria to a drug is primarily influenced by the concentration of the drug required to kill the bacteria and the rate at which the bacteria are killed at the appropriate concentration. This translates to efficacy because a drug that has a limited and pronounced zonal susceptibility and a slow killing rate will not demonstrate efficacy and therapeutic significance.

As part of our ongoing drug discovery program targeting FtsZ, three compounds were selected for more advanced *in vitro* characterization and efficacy testing. The *in vitro*–*in vivo* activity relationship of each of these compounds provides information about the drug exposure potential upon dosing in animal models of infection. MIC is the most common parameter used to prioritize a




Figure 3. Drug concentration response curves. Drug concentration response curves were generated for (A) Isoniazid, (B) SB-P3G2 and SB-P8B2 and (C) SB-P1G10 by graphing the log₁₀ drug concentrations (µg/mL) and % viability. Bacterial viability in the presence of different concentrations was determined by the microplate Alamar Blue assay (MABA) [9,19]. Bacteria were treated for 7 days before assessing viability.

Table 2

In vitro potency of SB-P8B2 and SB-P3G2 against non-replicating *M. tuberculosis* grown under low oxygen conditions.

	Concentration ($\mu\text{g/mL}$)	\log_{10} (CFU \pm SD)	\log_{10} (CFU) reduction	% Viable reduction
Control		5.35 ± 0.01	na	na
Isoniazid [*]	4	5.15 ± 0.2	0.2	36
	45	5.01 ± 0.32	0.34	54
Metronidazole [†]	4	4.83 ± 0.06	0.52	70
	45	3.39 ± 0.11	1.96	99
SB-P8B2 [‡]	4	4.96 ± 0.18	0.39	59
	45	4.38 ± 0.14	0.97	89
SB-P3G2 [‡]	4	4.87 ± 0.21	0.48	72

^{*} Isoniazid is not effective against non-replicating bacteria.

[†] Metronidazole is effective against non-replicating bacteria but has no efficacy against actively dividing bacteria.

[‡] Representative trisubstituted benzimidazoles.

drug candidate's progression into efficacy studies. However, MIC as a primary criterion has limitations, as it does not provide information about the rate of killing or the effective concentration of drug to achieve the rate of killing. Although the MIC of different drug candidates is similar, their kill-curve characteristics could be different resulting in observed difference in efficacy when delivered *in vivo*. The kill-curves generated for both SB-P3G2 and SB-P8B2 were concentration dependent and sigmoidal, indicating that as the concentration of the compound increases an inhibitory threshold is met and significant bactericidal activity is achieved. Importantly, the bactericidal activity is sustained despite significantly increased drug concentrations. This is consistent with the observed efficacy of SB-P3G2 in two different acute tuberculosis models of infection. These characteristics are typical of our lead compounds with efficacy in acute models of infection because at drug concentrations near the MIC the growth rate and number of viable bacteria are reduced, and the maximal effective dose range is large. This allows effective therapeutic concentrations to be maintained at the site of infection throughout the dosing interval. In contrast, the inhibition and dose–response curves generated for SB-P1G10 showed a pronounced zonal susceptibility similar to what has been described as the Eagle–Musselman phenomenon [11]. This type of kill-curve indicates that SB-P1G10 is bactericidal within a narrow range of concentrations centered on the MIC, but

any increase in compound concentration greater than the optimal levels significantly reduces the extent of bacterial death. Therefore, the effective therapeutic concentration for SB-P1G10 within the narrow zone of susceptibility/bactericidal activity is maintained for a very short time during dosing. Together, the efficacy studies with SB-P3G2 and SB-P1G10 revealed the *in vitro* activity–efficacy relationship for these drugs, and provides an explanation for the often observed disconnect between drug potency and treatment efficacy. This is further justified by a report, which demonstrates that bacterial tolerance is a result of drug exposure that has been shown to be the result of induction of stress responses [12]. This observation is consistent with the notion that compounds with a narrow zone of susceptibility will lack significant efficacy because of the limited achievable effective therapeutic concentrations.

A new drug for tuberculosis should be co-administrable with currently used clinical drugs, and should have activity against clinical strains with differing drug susceptibilities and potency against non-replicating persistent bacilli. We assessed whether the inhibition of cell division with SB-P8B2 was antagonistic when used in combination with rifampicin. The FICI for the rifampicin: SB-P8B2 combination was 0.63 indicating that these two drugs are not antagonistic. In addition, the activity of SB-P8B2 against *M. tuberculosis* was enhanced by 8-fold in the presence of rifampicin. Only a modest 2-fold increase in the activity of rifampicin was observed. It is thought that because bacterial adaption to stress, including the bacterial response to drug exposure, occurs at the level of protein synthesis, the observed enhancement of SB-P8B2 activity is the result of rifampicin preventing the bacterial response to treatment with SB-P8B2. These drug candidates were shown to be equally active against clinical isolates and the laboratory strain, which is expected because the molecular target of this class of inhibitors is not a molecular target for current clinically used compounds. It is well known that the frontline TB drug isoniazid is only active against replicating *M. tuberculosis* typical of acute infections, and does not effectively kill non-replicating persistent organisms. Therefore, to assess whether cell division inhibitors have activity against non-replicating persistent bacilli, we tested SB-P3G2 and SB-P8B2 and discovered that they were both effective against non-replicating bacteria. SB-P1G10 was not tested under these conditions because at higher concentrations the compound is bacteriostatic.




Figure 4. Efficacy in acute animal models of tuberculosis. (A) Scatter plots of the bacterial CFU counts from lungs (●) and spleen (▲) from untreated control animals and the lungs (■) and spleen (▼) of infected mice after treatment with SB-P3G2 delivered IP at 150 mg/kg for 9 consecutive days to immune incompetent GKO mice. SB-P3G2 reduced the bacterial load of *M. tuberculosis* H37Rv $0.71 \pm 0.17 \log_{10}$ CFU in the lungs and $0.41 \pm 0.36 \log_{10}$ CFU in spleen. (B) Scatter plots of the bacterial CFU counts from spleen (▲) from untreated control animals and the spleen (▼) of infected mice after treatment with SB-P3G2 delivered IP at 100 mg/kg BID for 10 consecutive days to immune competent C57BL/6 mice. SB-P3G2 reduced the bacterial load of *M. tuberculosis* Erdman in the spleen \log_{10} 1.6 ± 0.49 . In both studies, no outliers were identified by the Grubbs' Test.

5. Conclusion

A new anti-TB drug needs to be active against clinical strains with various drug susceptibility profiles as well as non-replicating persistent organisms. In addition, it should be co-administrable to improve treatment of chronic TB infections. We have reported here the *in vitro*–*in vivo* activity relationship of benzimidazole efficacy in murine models of tuberculosis. In addition, we have shown that selected benzimidazoles with this mode of action have activity against clinical isolates, as well as non-replicating persistent bacilli, and can enhance current therapeutic regimens. Together, these results substantiate that the molecular target FtsZ and this class of compounds warrants further study as a clinically relevant target and a novel class of chemotherapeutic agents for the treatment of tuberculosis.

Funding: This work was supported by grants AIO78251 (IO, RAS) and AIO82164 (RAS) from the National Institutes of Health.

Competing Interests: None Declared.

Ethical Approval: Not required.

References

- [1] Anon.. Tuberculosis fact sheet. World Health Organization; 2010.
- [2] Ravigione MC, Smith IM. XDR tuberculosis – implications for global public health. *N Engl J Med* 2007;356:656–9. <http://dx.doi.org/10.1056/NEJMp068273>.
- [3] Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. *Euro Surveill* 2007;12. E070517 070511.
- [4] Slayden RA, Knudson DL, Belisle JT. Identification of cell cycle regulators in *Mycobacterium tuberculosis* by inhibition of septum formation and global transcriptional analysis. *Microbiology* 2006;152:1789–97. <http://dx.doi.org/10.1099/mic.0.28762-0>.
- [5] Slayden RA, Belisle JT. Morphological features and signature gene response elicited by inactivation of FtsI in *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 2009;63:451–7. <http://dx.doi.org/10.1093/jac/dkn507>.
- [6] Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I. Discovery of anti-TB agents that target the cell-division protein FtsZ. *Future Med Chem* 2010;2:1305–23. <http://dx.doi.org/10.4155/fmc.10.220>.
- [7] Huang Q, Tonge PJ, Slayden RA, Kirikae T, Ojima I. FtsZ: a novel target for tuberculosis drug discovery. *Curr Top Med Chem* 2007;7:527–43.
- [8] Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ, Ojima I. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. *J Med Chem* 2006;49:463–6. <http://dx.doi.org/10.1021/jm050920y>.
- [9] Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. *J Med Chem* 2011;54:374–81. <http://dx.doi.org/10.1021/jm1012006>.
- [10] Mueller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. *Antimicrob Agents Chemother* 2004;48:369–77. <http://dx.doi.org/10.1128/aac.48.2.369-377.2004>.
- [11] Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. *J Exp Med* 1948;88:99–131.
- [12] Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. *Science* 2004;305:1629–31.
- [13] Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. *Science* 2004;305:1622–5. <http://dx.doi.org/10.1126/science.1099390>.
- [14] Camus JC, Pryor MJ, Medigue C, Cole ST. Re-annotation of the genome sequence of *Mycobacterium tuberculosis* H37Rv. *Microbiology* 2002;148:2967–73.
- [15] Miyoshi-Akiyama T, Matsumura K, Iwai H, Funatogawa K, Kirikae T. Complete annotated genome sequence of *Mycobacterium tuberculosis* Erdman. *J Bacteriol* 2012;194:2770. <http://dx.doi.org/10.1128/JB.00353-12>.
- [16] Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. *Antimicrob Agents Chemother* 2003;47:783–5.
- [17] Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1996;40:2809–12.
- [18] Slayden RA, Lee RE, Barry 3rd CE. Isoniazid affects multiple components of the type II fatty acid synthase system of *Mycobacterium tuberculosis*. *Mol Microbiol* 2000;38:514–25.
- [19] Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against *Mycobacterium tuberculosis* and *Mycobacterium avium*. *Antimicrob Agents Chemother* 1997;41:1004–9.
- [20] Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM. Preclinical testing of the nitroimidazopyran PA-824 for activity against *Mycobacterium tuberculosis* in a series of in vitro and in vivo models. *Antimicrob Agents Chemother* 2005;49:2294–301. <http://dx.doi.org/10.1128/AAC.49.6.2294-2301.2005>.
- [21] Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. *Antimicrob Agents Chemother* 2010;54:2840–6. <http://dx.doi.org/10.1128/AAC.01601-09>.